Representative Jake Auchincloss introduces H.R. 10857: Faster Clinical Trials Act

We have received text from H.R. 10857: Faster Clinical Trials Act. This bill was received on 2026-10-22, and currently has 1 cosponsor.

Here is a short summary of the bill:

The bill would create and expand several FDA programs aimed at speeding up medical research, improving how clinical trials are run, and strengthening oversight of drug development and labeling.

Clinical Trials and Research Infrastructure

The bill would establish an FDA-led Cures in Care program to make it easier to run routine clinical trials within ordinary health care settings. It would encourage the use of decentralized methods, including digital and AI-enabled tools, and would place priority on sites that serve underserved populations. The program would include lead trial networks, a public-private collaboration effort, training, reporting requirements, and new grant funding. It would authorize $500 million per year from 2027 through 2031.

The bill would also require more standardized and interoperable data sharing for these point-of-care trials. It would expand FDA and CMS guidance on how trials are paid for, allow privacy-protected data linkage, and update oversight rules for trial conduct. It would also modernize review of early-stage trials, support alignment with international standards, and require closer scrutiny of foreign data used in FDA decisions.

Rare Disease Support

The bill would create an FDA Rare Disease Innovation Hub to help speed rare disease trials, biomarker development, and collaboration with nontraditional sponsors. The hub would receive funding, form partnerships, and submit reports on its activities and progress.

Drug Review and Manufacturing Oversight

The bill would make several FDA process changes intended to reduce delays and improve review efficiency. These changes would address clinical holds, generic drug review, biosimilar review, and inspection processes. It would also update certain procedures related to early-phase clinical research and foreign-source data used in regulatory review.

Oncology and Genomic Labeling

The bill would establish an Oncology Center of Excellence and create a new FDA process for reviewing genomic exclusion labeling for cancer drugs. The FDA would identify oncology drugs that may need genomic exclusion warnings, set standards for those labels, encourage voluntary label updates, and provide expedited review. It would also require public reporting, issue guidance, and send reports to Congress. The bill would define the criteria for this process while preserving FDA authority over labeling decisions.

Relevant Companies

• ILMN — Illumina may be affected by expanded use of genomic information in drug labeling and oncology review, since its sequencing technologies are widely used in clinical and cancer testing workflows.
• TMO — Thermo Fisher Scientific could be affected by increased clinical trial activity, diagnostic testing, and research infrastructure spending, including work tied to decentralized trials and biomarker development.
• DHR — Danaher may be indirectly affected through its life sciences and diagnostics businesses if the bill increases clinical research, biomarker testing, and rare disease development activity.
• ABT — Abbott could be affected through diagnostic and clinical testing products used in trials, rare disease work, and oncology-related testing.
• RHHBY — Roche may be impacted by faster oncology review processes and genomic labeling changes, since it has a large cancer drug portfolio and diagnostics business.
• AMGN — Amgen could be affected by changes in biosimilar review, oncology oversight, and FDA review processes relevant to biologic drug development.
• REGN — Regeneron may be affected by changes in clinical trial policy, genomic labeling, and oncology-related FDA review practices.

Representative Jake Auchincloss Bill Proposals

Here are some bills which have recently been proposed by Representative Jake Auchincloss:

• H.R.10857: Faster Clinical Trials Act
• H.R.10138: CCP Fentanyl Sanctions Act
• H.R.9823: Alzheimer’s Early Detection Act of 2026
• H.R.7568: Hot Rock Act
• H.R.6837: To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes.
• H.R.6610: Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]

You can track bills proposed by Representative Jake Auchincloss on Investivoq's politician page for Auchincloss.

Representative Jake Auchincloss Net Worth

Investivoq estimates that Representative Jake Auchincloss is worth $4.5M, as of November 13th, 2026. This is the 181st highest net worth in Congress, per our live estimates.

Auchincloss has approximately $2.0M invested in publicly traded assets which Investivoq is able to track live.

You can track Representative Jake Auchincloss's net worth on Investivoq's politician page for Auchincloss.

Representative Jake Auchincloss Stock Trading

We have data on up to $500.0K of trades from Representative Jake Auchincloss, which we parsed from STOCK Act filings. Some of the largest trades include:

• A November 18th, 2024 sale of up to $50K of $STT. The stock has risen 80.71% since then.

You can track Representative Jake Auchincloss's stock trading on Investivoq's politician page for Auchincloss.

2026 Massachusetts's 4th Congressional District Election

There has been approximately $4,647,017 of spending in Massachusetts's 4th congressional district elections over the last two years, per our estimates.

Approximately $379,055 of this has been from outside spending by PACs and Super PACs.

The rating for this race is currently "Solid D".

You can track this election on our matchup page for the 2026 Massachusetts's 4th congressional district election.

This article is not financial advice. See Investivoq's disclaimers for more information.